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ABSTRACT
The role of paracrine Hepatocyte Growth Factor (HGF) in the resistance to 
angiogenesis inhibitors (AIs) is hidden in xenograft models because mouse HGF 
fails to fully activate human MET. To uncover it, we compared the efficacy of AIs in 
wild-type and human HGF knock-in SCID mice bearing orthotopic human colorectal 
tumors. Species-specific HGF/MET signaling dramatically impaired the response 
to anti-angiogenic agents and boosted metastatic dissemination. In cell-based 
assays mimicking the consequences of anti-angiogenic therapy, colorectal cancer 
cells were completely resistant to hypoxia but extremely sensitive to nutrient 
deprivation. Starvation-induced apoptosis could be prevented by HGF, which 
promoted GLUT1-mediated glucose uptake, sustained glycolysis and activated 
autophagy. Pharmacological inhibition of GLUT1 in the presence of glucose killed 
tumor cells as effectively as glucose deprivation, and this effect was antagonized 
by HGF. Concomitant targeting of GLUT1 and HGF potently suppressed growth and 
dissemination of AI-resistant human tumors in human HGF knock-in SCID mice 
without exacerbating tumor hypoxia. These data suggest that stroma-derived HGF 
protects CRC cells against glucose starvation-induced apoptosis, promoting resistance 
to both AIs and anti-glycolytic agents. Combined inhibition of glucose metabolism 
and HGF/MET signaling (‘anti-METabolic therapy’) may represent a more effective 
CRC treatment compared to utterly blocking tumor blood supply.
INTRODUCTION
Metastatic colorectal cancer (CRC) is one of the 
most common tumors in both men and women, and the 
second leading cause of cancer deaths worldwide [1]. The 
current approach to treating metastatic CRC favors the use 
of combination cytotoxic therapy (fluorouracil, leucovorin, 
oxaliplatin, capecitabine, irinotecan) plus biological 
agents targeting epidermal growth factor receptor (EGFR; 
cetuximab, panitumumab) [2]. More than half CRC 
patients, however, are not eligible to EGFR-targeted 
therapy because they bear KRAS- or BRAF-mutant tumors 
[3]. These patients, as well as those that have developed 
resistance to cetuximab or panitumumab, are typically 
addressed towards treatment with anti-angiogenic agents 
(bevacizumab, ziv-aflibercept, regorafenib) [4].
Angiogenesis inhibitors (AIs), and in particular 
bevacizumab, achieved encouraging results in advanced 
CRC [5, 6]. However, clinical testing of AIs in the adjuvant 
setting -where these kind of drugs are expected to be more 
effective based on their mechanism of action- was a major 
failure [7, 8]. Furthermore, most clinical trials testing 
agents targeting the vascular endothelial growth factor 
(VEGF) pathway in CRC provided evidence for increased 
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progression-free survival but failed to demonstrate a 
substantial overall survival benefit, suggesting that anti-
angiogenic treatment induces a biological adaptation 
leading to disease modification [9].
The biological mechanisms underlying resistance to 
AIs are not fully understood. Tumor hypoxia consequent 
to vessel pruning has been identified as a major cause of 
therapeutic failure and relapse [10]. It has been proven 
that a hypoxic micro-environment leads to clonal selection 
of tumor cells with increased invasive potential [11]. It 
has also been shown that hypoxia activates an invasive 
growth program orchestrated by hepatocyte growth factor 
(HGF) that leads cancer cells away from the hypoxic area, 
enabling them to escape anti-angiogenic therapy [12-14]. 
Finally, it has been demonstrated that AI-induced hypoxia 
cause tumor cells to rewire their glucose metabolism 
to fit the new micro-environment [15-17], although 
the molecular mechanisms and the cell-to-cell signals 
underlying this adaptation are still obscure.
HGF is a pleiotropic cytokine of mesenchymal origin 
that controls cell proliferation, motility, differentiation, 
and survival [18]. Its high affinity receptor, the MET 
tyrosine kinase, is frequently deregulated in human cancer 
[19]. HGF-driven MET activation plays a pivotal role in 
colorectal tumorigenesis and progression [20]. The vast 
majority of colorectal tumors express or overexpress 
the MET protein [21], and clinical findings indicate that 
activation of the MET pathway is a poor prognostic factor 
in CRC patients [22]. Although HGF/MET signaling 
typically controls epithelial-to-mesenchymal transition, 
a number of recent studies suggest that it may also be 
involved in the regulation of glucose metabolism [23-25].
In this study we hypothesized that HGF/MET 
signaling could be responsible not only for allowing CRC 
cells to physically escape anti-angiogenic therapy, but 
also for rewiring their metabolism in response to vessel 
pruning. To investigate this possibility, we exploited the 
inability of mouse HGF to fully activate human MET 
[26-28]. In fact, MET activation in colorectal tumors 
occurs primarily via paracrine HGF stimulation by the 
surrounding stroma [29]. When human cancer cells are 
transplanted into immuno-deficient mice, the growth of 
the developing tumor (expressing human MET) cannot 
be fully sustained by micro-environment-derived HGF 
(secreted by mouse stroma cells). Therefore, standard 
xenograft models do not represent an ideal system where 
to study the biological effects of paracrine HGF signaling.
We recently described the use of human HGF 
knock-in (hHGF KI) SCID mice for studying the role of 
stroma-derived HGF in the resistance to MET inhibitors 
[30]. In this mouse strain, the endogenous HGF gene has 
been replaced by homologous recombination with a cDNA 
encoding human HGF. Since human HGF activates both 
human and mouse MET, these animals are vital and fertile, 
and thanks to the SCID background, they support the 
growth of human tumor xenotransplants [30]. In contrast 
to transgenic mice that overexpress human HGF on top 
of mouse HGF [28], hHGF KI SCID mice express human 
HGF in place of mouse HGF, and since expression of 
the human gene is driven by the endogenous HGF gene 
promoter, hHGF KI SCID mice display fully physiological 
HGF expression levels [30].
To unmask the role of micro-environment-derived 
HGF in the response of CRC to AIs, we orthotopically 
injected human CRC cells bearing KRAS or BRAF 
mutations into wild-type (WT) and hHGF KI SCID mice, 
and compared the efficacy of different anti-angiogenic 
drugs in these two strains. To determine the effect of 
HGF on tumor metabolism, we compared the expression 
of glucose transporters in WT and hHGF KI SCID mice 
subjected to anti-angiogenic therapy. Finally, to dissect the 
mechanism by which HGF affects the cellular response to 
angiogenesis inhibition, we simulated the environmental 
conditions set by anti-angiogenic therapy in culture, and 
tested the impact of HGF on both classical biological 
parameters (proliferation, survival, motility) and 
cellular metabolic functions (glucose uptake, glycolysis, 
autophagy).
RESULTS
An orthotopic mouse model of colorectal cancer 
reproduces the tumor micro-environmental 
conditions and metastatic pattern found in cancer 
patients
To recapitulate the micro-environmental HGF/MET 
signaling conditions found in those oncological patients 
typically addressed towards anti-angiogenic therapy, we 
employed hHGF KI SCID mice (Suppl. Figure S1A) and 
MET-expressing human CRC cells bearing mutant KRAS 
(HCT-116) or BRAF (HT-29). HCT-116 and HT-29 cells, 
which displayed HGF-dependent MET activation (Suppl. 
Figure S1B), were engineered to express luciferase (luc) 
in order to track tumors and metastases. Micro-injection 
of HCT-116-luc and HT-29-luc cells into the cecum 
submucosa of hHGF KI SCID mice gave rise to orthotopic 
tumors within a few days, which could be monitored 
over time by bioluminescence analysis (Suppl. Figure 
S1C). Both HCT-116 and HT-29 tumors reproduced the 
pattern of metastatic dissemination observed in the clinic, 
which mainly involves the liver and the lungs. Metastases 
could be detected by histological examination and by 
bioluminescence analysis of explanted organs (Suppl. 
Figure S1D).
Micro-environment-derived HGF promotes 
resistance to angiogenesis inhibitors
Human HCT-116-luc and HT-29-luc cells were 
orthotopically micro-injected into WT or hHGF KI 
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SCID mice. Tumor-bearing animals were assigned to 
3 treatment arms, which received no treatment, 15 mg/
kg bevacizumab, or 10 mg/kg tivozanib (a pan-VEGF 
receptor small molecule inhibitor) [31]. Tumor growth 
and metastatic dissemination were assessed by in vivo 
and ex vivo imaging. Remarkably, both HCT-116 (Figure 
1A) and HT-29 (Figure 1B) tumors grew significantly 
faster in hHGF KI SCID mice compared to WT SCID 
Figure 1: Micro-environment-derived HGF promotes resistance of orthotopic colorectal tumors to angiogenesis 
inhibitors. A. HCT-116-luc cells were injected orthotopically into wild-type (WT) or human HGF knock-in (hHGF KI) SCID mice, and 
tumor-bearing mice were randomly assigned to 3 treatment arms: control (CTR), 15 mg/kg bevacizumab (BEV), and 10 mg/kg tivozanib 
(TIV). Tumor growth was followed over time by in vivo bioluminescence (IVBL). B. Same as in A but using HT-29-luc cells. C. Mean 
vessel density (MVD) of HCT-116 and HT-29 tumor tissues was determined by IHC using anti-CD146 antibodies. Values represent mean 
± SEM. Statistical significance was calculated using a Student’s T-test (A and B, n = 7; C, n = 21).
Oncotarget38196www.impactjournals.com/oncotarget
mice. Furthermore, while AIs markedly reduced tumor 
growth in WT SCID mice, they displayed a dramatically 
reduced therapeutic effect -if any- in hHGF KI SCID 
mice. Tumor micro-vessel density analysis revealed that 
impaired efficacy of AIs in hHGF KI SCID mice was not 
due to lack of anti-angiogenic activity (Figure 1C). In both 
tumor systems, angiogenesis inhibition by bevacizumab 
or tivozanib resulted in increased tumor hypoxia in either 
hHGF KI or WT SCID mice (Figure 2A), as determined 
by hypoxiprobe and carbonic anhydrase IX (CAIX) 
Figure 2: Anti-angiogenic therapy of orthotopic colorectal tumors promotes hypoxia-mediated, HGF-dependent MET 
activation. A. Tumor hypoxia in HCT-116 and HT-29 tumors was determined by IHC using hypoxiprobe and anti-carbonic anhydrase IX 
(CAIX) antibodies. B. MET expression in HCT-116 and HT-29 tumors was determined by IHC analysis using anti-human MET antibodies. 
C. MET activation in HCT-116 and HT-29 tumors was determined by IHC analysis using anti-phospho MET antibodies. See Suppl. Figure 
S2 for representative images and score system description. Values represent mean ± SEM. Statistical significance was calculated using a 
Student’s T-test (n = 7).
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staining (see Suppl. Figure S2 for score system definition). 
Angiogenesis inhibition increased tumor hypoxia 
independently of species-specific HGF signaling (see 
Suppl. Figure S3 for representative images). Angiogenesis 
inhibition also increased MET expression in both hHGF 
KI and WT SCID animals (Figure 2B), but resulted in 
higher phospho-MET levels in hHGF KI SCID mice 
only (Figure 2C). These data suggest that species-specific 
HGF/MET signaling promotes resistance to AIs that is 
independent of the ability of the drugs to impair tumor 
angiogenesis.
Anti-angiogenic therapy of orthotopic colorectal 
tumors promotes HGF-dependent metastatic 
dissemination
Bioluminescence analysis of isolated organs 
revealed that metastatic dissemination was markedly 
HGF-dependent. In fact, livers and lungs extracted from 
hHGF KI SCID mice bearing HCT-116 (Figure 3A) 
or HT-29 (Figure 3B) tumors displayed dramatically 
higher bioluminescence levels compared to livers and 
lungs extracted from WT SCID animals. Autoptical and 
histological analysis confirmed this observation (see figure 
inset). Moreover, while anti-angiogenic therapy did not 
substantially affect liver or lung metastases in WT SCID 
mice, it strikingly enhanced both hepatic and pulmonary 
metastases in hHGF KI SCID mice, in both the HCT-116 
(Figure 3A) and the HT-29 (Figure 3B) models. These 
data confirm the idea that CRC cells quickly adapt to anti-
angiogenic therapy by engaging a HGF-dependent escape 
mechanism that leads them to disseminate into the host 
organism.
HGF protects colorectal cancer cells against 
glucose starvation-induced apoptosis
By pruning tumor vessels, anti-angiogenic therapy 
increases tumor hypoxia and deprives cancer cells of 
nutrients, dramatically reducing glucose availability [32, 
Figure 3: Anti-angiogenic therapy of orthotopic colorectal tumors promotes HGF-dependent metastatic dissemination. 
A. Hepatic and pulmonary metastases in mice bearing HCT-116 tumors were determined by ex vivo bioluminescence (EVBL) analysis of 
explanted organs and by histological examination of tissue sections (inset). B. Same as in A but using mice bearing HT-29 tumors. Values 
represent mean ± SEM. Statistical significance was calculated using a Student’s T-test (n = 7). Bar size: 250 µm.
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33]. In order to dissect the mechanism by which micro-
environment-derived HGF protects CRC cells against anti-
angiogenic treatment, we subjected HCT-116 and HT-29 
cells to progressively lower concentrations of oxygen or 
glucose in the absence or presence of HGF. In both cell 
lines tested, oxygen deprivation did not cause apoptosis 
(Figure 4A) but rather G0/G1 arrest (Suppl. Figure S4A). 
In contrast, glucose deprivation dramatically increased 
the apoptotic rate (Figure 4B), causing a sub-G1 boost 
(see figure inset) and a striking S and G2/M drop (Suppl. 
Figure S4B). While HGF did not substantially affect cell 
viability in low oxygen, it contrasted hypoxia-induced 
cell cycle arrest, partially rescuing cell proliferation. 
Most remarkably, HGF protected CRC cells against 
glucose starvation-induced apoptosis, preventing the 
sub-G1 surge. We extended this analysis to a wider panel 
of MET-expressing human CRC cell lines with different 
genetic status (Suppl. Fig. S5). As shown in Table 1, cells 
bearing mutations in KRAS or BRAF, including HCT-116 
and HT-29, were dramatically more sensitive to glucose 
deprivation compared to cells with WT KRAS and BRAF, 
and their survival in low glucose could be rescued by 
HGF. Oxygen deprivation had little effect on survival, 
regardless of genetic status. Altogether, these data suggest 
that KRAS- and BRAF-mutant CRC cells rely on glucose 
much more strictly than they depend on oxygen for 
survival, and that HGF extends the permissive range of 
glucose concentration.
Figure 4: Oxygen and nutrient availability differentially affect colorectal cancer cell survival and proliferation. A. 
HCT-116 and HT-29 cells were incubated in progressively lower oxygen concentrations in the absence or presence of HGF, and apoptosis 
was determined by the annexin/propidium iodide method. The percentage of cells in Sub-G1 (inset) was determined by DNA content 
analysis (see Suppl. Figure S3 for full cell cycle distribution data). B. HCT-116 and HT-29 cells were incubated in progressively lower 
glucose concentrations in the absence or presence of HGF. Apoptosis and cell cycle distribution was determined as in A. Values represent 
mean ± SEM. Statistical significance was calculated using a Student’s T-test (n = 3).
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HGF sustains colorectal cancer cell invasion in 
hypoxic conditions
Increased MET expression and HGF-dependent 
invasion under hypoxia has been described years 
ago and has been subsequently confirmed by other 
studies conducted in several model systems, including 
glioblastoma and pancreatic cancer [12-14]. To explore 
the effect of hypoxia in CRC models, we determined 
HCT-116 and HT-29 cell invasiveness in different oxygen 
atmospheres. In this set of experiments, hypoxia promoted 
MET mRNA expression (Figure 5A), increased MET 
protein levels exposed on the cell membrane (Figure 
5B) and sensitized cells to HGF stimulation (Figure 5C). 
Moreover, hypoxia synergized with HGF in promoting 
branching morphogenesis (Figure 5D), selected for a more 
aggressive cell population that displayed higher MET 
levels and enhanced anchorage-independent cell growth 
in response to HGF (Figure 5E). These data indicate that 
hypoxia promotes HGF-dependent malignant progression 
of CRC cells, providing a mechanistic explanation for the 
higher metastatic levels observed in hHGF KI SCID mice 
treated with AIs.
HGF promotes glucose uptake and sustains 
glycolysis by inducing GLUT1 expression
HGF increased glucose consumption by HCT-116 
and HT-29 cells in both high (4.5 g/L) and low (0.5 g/L) 
glucose culturing conditions (Figure 6A), accompanied by 
higher lactate production (Figure 6B). To explore the role 
of HGF in regulating glycolysis, we incubated HCT-116 
and HT-29 cells in decreasing glucose concentrations (4.5-
0.125 g/L) in the absence or presence of HGF, and then 
measured glycolytic capacity in the presence of saturating 
glucose concentrations. Remarkably, HGF stimulation 
significantly enhanced the ability of CRC cells to perform 
glycolysis in limiting glucose concentrations (Figure 6C). 
To explore whether HGF directly affected glucose uptake, 
we cultured HCT-116 and HT-29 cells in high (4.5 g/L) 




at 0.1 g/L glucose
CELL LINE KRAS BRAF CTR HGF CTR HGF
CACO-2 WT WT 3.7 ± 0.1 2.5 ± 0.2 7.3 ± 0.4 4.2 ± 0.1
COLO-320-DM WT WT 3.3 ± 0.2 2.4 ± 0.2 6.5 ± 0.4 3.3 ± 0.2
LIM-1215 WT WT 3.6 ± 0.3 2.4 ± 0.2 5.7 ± 0.4 4.1 ± 0.2
SW-48 WT WT 4.6 ± 0.4 3.6 ± 0.2 6.5 ± 0.4 3.9 ± 0.2
DLD-1 G13D WT 5.7 ± 0.4 4.3 ± 0.2 38.4 ± 1.3 20.6 ± 0.8
HCT-116 G13D WT 6.7 ± 1.2 4.5 ± 0.9 40.4 ± 1.8 21.4 ± 1.8
LOVO G13D WT 6.0 ± 0.4 4.4 ± 0.4 33.6 ± 1.0 17.1 ± 0.7
LS-1034 A146T WT 5.0 ± 0.4 3.0 ± 0.2 25.5 ± 1.7 12.5 ± 0.6
LS-123 G12S WT 5.2 ± 0.6 2.8 ± 0.3 20.1 ± 1.0 11.0 ± 0.9
LS-174T G12D WT 6.1 ± 0.4 4.3 ± 0.4 32.4 ± 1.2 20.5 ± 0.6
LS-180 G12D WT 6.6 ± 0.4 4.5 ± 0.3 26.1 ± 1.2 14.0 ± 0.7
SW-480 G12V WT 5.9 ± 0.2 4.0 ± 0.1 24.0 ± 0.9 12.3 ± 0.9
HT-29 WT V600E 7.5 ± 0.8 4.3 ± 0.3 22.9 ± 2.2 12.6 ± 1.3
RKO WT V600E 5.2 ± 0.3 3.0 ± 0.2 24.5 ± 0.6 12.1 ± 0.8
SW-1417 WT V600E 4.4 ± 0.2 2.1 ± 0.2 24.2 ± 0.8 11.8 ± 0.9
A panel of human CRC cell lines with different KRAS and BRAF status was subjected to progressively lower concentrations of 
oxygen or glucose in the absence or presence of HGF, and the percentage of apoptotic cells was determined by flow cytometry 
using the annexin V/propidium iodide method. Values represent the mean ± SEM of 3 different measurements. CTR, control.
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Figure 5: HGF sustains colorectal cancer cell invasion in hypoxic conditions. A. MET mRNA levels in HCT-116 and HT-
29 cells incubated in hypoxia (1% O2) were determined by RT-PCR. Data are expressed as 2-∆∆Ct compared to time zero. B. MET protein 
expression levels in HCT-116 and HT-29 cells incubated in hypoxia (1% O2) were determined by flow cytometry. MFI, mean fluorescence 
intensity. C. HCT-116 and HT-29 cells were pre-conditioned in 21% or 1% O2 and then stimulated with HGF. Phospho-MET (pMET) and 
total MET (MET) levels were determined by Western blotting (WB). NS, not stimulated. The upper 170 kDa MET band corresponds to the 
uncleaved, immature precursor. D. Collagen invasion by HCT-116 and HT-29 cells was determined in 21% or 1% O2 and in the absence 
or presence of HGF. Branching morphogenesis was analyzed by microscopy. Colony contour is highlighted with a white dotted line. Bar 
size: 500 µm. E. Anchorage-independent growth of HCT-116 and HT-29 cells pre-conditioned in 21% or 1% O2 was examined in a soft 
agar assay conducted in normoxia and in the absence or presence of HGF. Cells pre-conditioned in 1% O2 expressed higher levels of MET 
protein (see FACS inset). Values represent mean ± SEM. Statistical significance was calculated using a Student’s T-test (n = 3).
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Figure 6: HGF sustains glycolysis in low glucose by promoting GLUT1-mediated glucose uptake. A. Glucose consumption 
by HCT-116 and HT-29 cells grown in high (4.5g/L) or low (0.5g/L) glucose-containing medium and in the absence or presence of HGF 
was determined over a period of 24 hours. B. Same as in A but measuring lactate production. C. Glycolytic capacity (GC) of HCT-116 
and HT-29 cells pre-incubated in progressively lower glucose concentrations and in the absence or presence of HGF was determined by 
Seahorse technology. GC is expressed as % relative to full glucose. D. Incorporation of the fluorescent glucose analogue 2-NBDG was 
determined by flow cytometry in HCT-116 and HT-29 cells pre-incubated in high (4.5g/L) or low (0.5g/L) glucose-containing medium and 
in the absence or presence of HGF. NEG, negative control. E. GLUT1 mRNA levels were determined by RT-PCR analysis of HCT-116 and 
HT-29 cells grown in high (4.5g/L) or low (0.5g/L) glucose-containing medium and in the presence of increasing HGF concentrations. Data 
are expressed as 2−ΔΔCt compared to cells without HGF. F. GLUT1 protein levels were determined by flow cytometry analysis of HCT-116 
and HT-29 cells grown in decreasing glucose concentrations and in the absence or presence of HGF. MFI, mean fluorescence intensity. 
Values represent mean ± SEM. Statistical significance was calculated using a Student’s T-test (n = 3).
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or low (0.5 g/L) glucose concentrations in the absence 
or presence of HGF, and then incubated them with the 
fluorescent glucose analog 2-(N-(7-Nitrobenz-2-oxa-1,3-
diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG). Glucose 
uptake was determined by flow cytometry. As shown 
in Figure 6D, HGF enhanced 2-NBDG uptake in both 
HCT-116 and HT-29 cells, and this effect was greater if 
cells were previously cultured in low glucose conditions. 
Consistent with this, HGF promoted the transcription of 
the SLC2A1 gene (Figure 6E), resulting in higher GLUT1 
protein levels (Figure 6F). Altogether, these data suggest 
that paracrine HGF signaling sustains CRC cell survival 
in limiting glucose concentrations by optimizing the 
efficiency of glucose influx and utilization.
HGF potentiates colorectal cancer cell autophagic 
flux under glucose starvation
Growing evidence points at autophagy as one 
of the mechanisms that cancer cells adopt to escape 
the metabolically challenging conditions set by anti-
angiogenic therapy [34]. To investigate a possible role of 
HGF in controlling autophagy, HCT-116 and HT-29 cells 
were incubated in high (4.5 g/L) or low (0.5 g/L) glucose, 
and in the absence or presence of HGF. Cells were also 
incubated with or without chloroquine, an inhibitor of 
lysosomal pH-dependent protein degradation. Changes 
in the autophagic flux were measured by Western blot 
analysis of microtubule-associated protein light chain 
3 (LC3). In high glucose, HGF significantly increased 
LC3 lipidation in the presence of chloroquine (Figure 
7A). In low glucose, a condition that typically induces 
an autophagic response, HGF increased LC3 lipidation 
per se and also enhanced chloroquine-induced LC3 
lipidation. To obtain more quantitative data, we measured 
autophagosome-associated LC3 levels by flow cytometry. 
This analysis revealed that HGF enhanced autophagic flux 
much more markedly in low glucose compared to high 
glucose (Figure 7B). We also determined the number of 
autophagosomes under different culturing conditions. 
HCT-116 and HT-29 cells were transduced with a lentiviral 
vector encoding a GFP-LC3 fusion protein and then 
Table 2: KRAS/BRAF-mutant CRC cells exhibit marked sensitivity to pharmacological GLUT1 blockade.
% cell viability
at 20 µmol/L WZB-117
CELL LINE KRAS BRAF CTR HGF
CACO-2 WT WT 62.5 ± 2.8 74.3 ± 0.8
COLO-320-DM WT WT 58.2 ± 1.3 73.8 ± 1.2
LIM-1215 WT WT 63.2 ± 1.4 74.4 ± 1.5
SW-48 WT WT 63.1 ± 1.7 75.9 ± 1.7
DLD-1 G13D WT 32.5 ± 1.5 65.0 ± 1.9
HCT-116 G13D WT 28.7 ± 1.4 67.5 ± 2.5
LOVO G13D WT 27.3 ± 0.6 67.2 ± 1.0
LS-1034 A146T WT 40.8 ± 0.9 61.9 ± 1.5
LS-123 G12S WT 46.1 ± 0.9 67.3 ± 1.1
LS-174T G12D WT 34.0 ± 1.8 66.4 ± 1.4
LS-180 G12D WT 34.2 ± 0.9 63.0 ± 1.5
SW-480 G12V WT 35.6 ± 0.9 60.8 ± 1.1
HT-29 WT V600E 44.0 ± 0.7 66.4 ± 1.5
RKO WT V600E 39.1 ± 0.7 70.6 ± 1.0
SW-1417 WT V600E 42.1 ± 1.5 65.9 ± 0.8
A panel of human CRC cell lines with different KRAS and BRAF status was incubated with increasing concentrations (0.01-
100 μmol/L) of WZB-117 in the absence or presence of HGF. Cell viability was determined by total ATP analysis. Values, 
expressed as % relative to untreated cells, represent the mean ± SEM of 3 different measurements. CTR, control.
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Figure 7: HGF potentiates colorectal cancer cell autophagic flux under glucose starvation. A. HCT-116 and HT-29 cells 
were incubated in high (4.5 g/L) or low (0.5 g/L) glucose, in the absence or presence of HGF, and with or without chloroquine (CQ). LC3 
lipidation was determined by Western blotting (WB) using anti-LC3 antibodies. The same blots were also analyzed using anti-vinculin 
antibodies. NS, not stimulated. The arrows indicate the lipidated LC3 isoform (LC3-II). B. HCT-116 and HT-29 cells were incubated as 
in A, permeabilized, and the cytosolic LC3 fraction was washed out. Autophagosome-associated LC3 levels were determined by flow 
cytometry. MFI, mean fluorescent intensity. C. HCT-116 and HT-29 cells ectopically expressing a GFP-LC3 fusion protein were cultured 
in high (4.5g/L) or low (0.5g/L) glucose-containing medium and in the absence or presence of HGF. The number of fluorescent GFP-LC3 
puncta (corresponding to autophagosomes) was determined by confocal microscopy. Nuclei were stained with DAPI, and the number of 
fluorescent puncta was normalized on the number of DAPI-positive nuclei. Bar size: 20 µm. Values represent mean ± SEM. Statistical 
significance was calculated using a Student’s T-test (B, n = 3; C, n = 10).
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incubated in high or low glucose as above. The number 
of fluorescent puncta (corresponding to autophagosomes) 
per cell was determined by confocal microscopy. These 
experiments confirmed that HGF stimulation enhances 
autophagy more potently in cells that are grown in limiting 
glucose concentrations (Figure 7C). Altogether, these 
results suggest that paracrine HGF signaling increases 
CRC cell survival in glucose-poor conditions by activating 
autophagy, thereby contributing to maintain energy 
balance.
Resistance to angiogenesis inhibitors in human 
HGF knock-in SCID mice is associated with HGF-
dependent GLUT1 overexpression
The data presented so far suggest that HGF 
promotes a metabolic ‘salvage’ program allowing CRC 
cells to avoid an energetic crash when facing glucose 
shortage. We reasoned that pharmacological blockade 
of HGF/MET signaling could prevent this adaptive 
process and overcome acquired resistance to AIs. To test 
this hypothesis, we orthotopically micro-injected HCT-
116-luc and HT-29-luc cells into hHGF KI SCID mice 
as described above, and then randomly assigned tumor-
bearing animals to the following arms: no treatment; 
15 mg/kg bevacizumab; 10 mg/kg tivozanib; 40 mg/kg 
JNJ-38877605 (a MET-selective small molecule tyrosine 
kinase inhibitor) [30]; 20 mg/kg ficlatuzumab (a HGF-
neutralizing antibody) [35]; 15 mg/kg bevacizumab plus 
40 mg/kg JNJ-38877605; 10 mg/kg tivozanib plus 40 
mg/kg JNJ-38877605; and 10 mg/kg tivozanib plus 20 
mg/kg ficlatuzumab. Treatment continued for 4 weeks. 
Remarkably, MET inhibition by JNJ-38877605 or HGF 
neutralization by ficlatuzumab completely restored 
sensitivity to anti-angiogenic therapy in both HCT-116 
(Figure 8A) and HT-29 (Figure 8B) tumors. Moreover, 
although MET/HGF blockade did not prevent AI-induced 
hypoxia, it fully suppressed metastatic spreading of 
both HCT-116 and HT-29 CRC cells to either the liver 
Figure 8: HGF/MET inhibition restores sensitivity to angiogenesis inhibitors in human HGF knock-in SCID mice. 
A. HCT-116-luc cells were injected orthotopically into human HGF knock-in (hHGF KI) SCID mice, and tumor-bearing animals were 
randomly assigned to 8 treatment arms: control (CTR), 15 mg/kg bevacizumab (BEV), 10 mg/kg tivozanib (TIV), 40 mg/kg JNJ-38877605 
(JNJ), 20 mg/kg ficlatuzumab (FCL), 15 mg/kg bevacizumab plus 40 mg/kg JNJ-38877605 (BEV+JNJ), 10 mg/kg tivozanib plus 40 mg/
kg JNJ-38877605 (TIV+JNJ), and 10 mg/kg tivozanib plus 20 mg/kg ficlatuzumab (TIV+FCL). Tumor growth was followed over time 
by in vivo bioluminescence (IVBL). Results are shown in 2 different graphs for clarity. B. Same as in A but using HT-29-luc cells. Values 
represent mean ± SEM. Statistical significance was calculated using a Student’s T-test (B, n = 7).
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(Figure 9A) or the lungs (Figure 9B). Interestingly, and 
consistent with our hypothesis that glycolytic rewiring is 
associated with resistance to AIs, anti-angiogenic therapy 
dramatically increased GLUT1 expression in both HCT-
116 (Figure 10A) and HT-29 (Figure 10B) tumors, which 
could be fully reversed by HGF/MET inhibition. These 
results suggest that resistance of colorectal tumors to 
AIs is associated with HGF/MET-dependent GLUT1 
overexpression.
Pharmacological GLUT1 blockade impairs 
colorectal cancer cell survival which can be 
rescued by paracrine HGF signaling
HCT-116 and HT-29 cells were incubated with 
increasing concentrations (0.01-100 μmol/L) of the bis-
hydroxybenzoate compound WZB-117, an irreversible 
blocker of GLUT1 [36], in the absence or presence of 
HGF. Cell viability was determined by total ATP analysis. 
As shown in Figure 11A, WZB-117 inhibited the growth 
of both HCT-116 and HT-29 cells in dose-dependent 
fashion, with an EC50 at 1.0 g/L glucose of 6.7 μmol/L 
and 11.2 μmol/L, respectively. HGF significantly protected 
HCT-116 and HT-29 cells against GLUT1 inhibition, 
increasing the EC50 by approximately one log (HCT-
116, 53.7 μmol/L; HT-29, > 100 μmol/L). This analysis 
was extended to the same CRC cell panel used above for 
oxygen vs. glucose dependency. Consistent with their 
extraordinary vulnerability in low glucose conditions, 
KRAS- and BRAF-mutant CRC cells were significantly 
more sensitive to GLUT1 blockade compared to cells 
with WT KRAS and BRAF (Table 2). As seen for glucose 
deprivation, HGF antagonized the effect of WZB-117 and 
rescued cell survival in all cells analyzed. We next tested 
specifically whether HGF could protect CRC cells against 
WZB-117-induced apoptosis. HCT-116 and HT-29 cells 
were incubated in decreasing concentrations of glucose 
(4.5-0.06 g/L), with or without WZB-117, and in the 
presence or absence of HGF. Apoptosis was determined 
by flow cytometry using the annexin/propidium iodide 
method. As shown in Figure 11B, WZB-117 increased 
the apoptotic rate of both HCT-116 and HT-29 cells, 
and its pro-apoptotic effect was inversely proportional 
Figure 9: HGF/MET inhibition suppresses both spontaneous and angiogenesis inhibitor-induced metastatic spreading 
in human HGF knock-in SCID mice. A. HCT-116-luc and HT-29-luc hepatic metastases were determined by ex vivo bioluminescence 
(EVBL) analysis of explanted livers. B. HCT-116-luc and HT-29-luc pulmonary metastases were determined by EVBL analysis of explanted 
lungs. Values represent mean ± SEM. Statistical significance was calculated using a Student’s T-test (n = 7).
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to glucose concentration. HGF stimulation significantly 
protected CRC cells against WZB-117-induced apoptosis 
at any glucose concentration. Finally, we tested the 
effects of WZB-117 and HGF in a stroma-tumor co-
culture system using human colon myofibroblasts 
secreting approximately 1 μmol HGF/106 cells/24 hours 
and luciferase-expressing CRC cells. HCT-116-luc or 
HT-29-luc cells were co-seeded with HGF-secreting 
myofibroblasts and then cultured with or without WZB-
117 in the presence or absence of ficlatuzumab. Tumor cell 
viability was determined by measuring luciferase activity. 
As shown in Figure 11C, stromal cells protected CRC cells 
against WZB-111-induced apoptosis, and this effect could 
be neutralized by pharmacological inhibition of HGF.
Concomitant inhibition of GLUT1 and HGF 
suppresses growth and dissemination of colorectal 
tumors resistant to anti-angiogenic inhibitors 
without exacerbating tumor hypoxia
The results presented so far provide experimental 
evidence that glucose withdrawal and not oxygen 
deprivation is crucial for killing KRAS/BRAF-mutant CRC 
cells, and that environmental HGF protects CRC cells 
against metabolic stress through GLUT1 upregulation. 
We therefore reasoned that selective targeting of GLUT1 
would have been a cleaner and more effective therapeutic 
approach compared to generalized cutting of tumor 
Figure 10: Resistance to angiogenesis inhibitors in human HGF knock-in SCID mice is associated with HGF-dependent 
GLUT1 overexpression. A. GLUT1 protein expression was determined by staining sections form the HCT-116 tumors described in 
Figure 8A with a human GLUT1 antibody. Bar size: 250 µm. B. GLUT1 protein expression was determined by staining sections from the 
HT-29 tumors described in Figure 8B with a human GLUT1 antibody. Bar size: 250 µm.
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blood supply, and that neutralization of HGF would 
have overcome micro-environment-mediated resistance 
to glucose uptake blockade. To test this hypothesis, we 
subjected hHGF KI SCID mice bearing orthotopic HCT-
116-luc and HT-29-luc tumors to the following treatments: 
control; 20 mg/kg ficlatuzumab; 10 mg/kg WZB-117; 10 
mg/kg WZB-117 plus 20 mg/kg ficlatuzumab. Tumor 
growth and metastatic dissemination was determined as 
described above. The results of this analysis provided 
relevant feedback on our work hypothesis. First, WZB-117 
inhibited colorectal tumor growth much more effectively 
than AIs in the same conditions (Figure 12A vs. Figure 
1A-B). Second, in contrast to anti-angiogenic therapy, 
selective targeting of GLUT1 not only did not promote 
metastatic dissemination, but actually significantly 
inhibited it (Figure 12B vs. Figure 3A-B). Third, 
neutralization of HGF by ficlatuzumab cooperated with 
metabolic blockade by WZB-117, inhibiting tumor growth 
and suppressing metastatic dissemination. Fourth and 
most important, and in striking contrast to AIs, GLUT1 
inhibition did not exacerbate tumor hypoxia (Figure 12C 
vs. Figure 2A and Suppl. Figure S3).
DISCUSSION
The strikingly different efficacy of AIs in WT 
and hHGF KI SCID mice suggests that stroma-derived 
HGF represents a major source of resistance to anti-
angiogenic therapy of metastatic colorectal cancer, at 
least in the orthotopic models analyzed. Our cellular 
and metabolic analysis indicates that this phenomenon is 
explained by two major mechanisms, corresponding to 
distinct biological activities of HGF. On one hand, tumor 
hypoxia -exacerbated by anti-angiogenic drugs- sensitizes 
surviving CRC cells to paracrine HGF stimulation, 
which enhances tumor cell motility and invasion, thus 
allowing CRC cells to escape therapy and to form 
secondary colonies in distant organs. This mechanism 
confirms studies performed in other model systems 
[13, 14] and explains the higher incidence of metastasis 
observed in AI-treated hHGF KI SCID mice. On the other 
hand, stroma-derived HGF protects CRC cells against 
glucose starvation-induced apoptosis, allowing them to 
survive longer in a poorly vascularized tumor. The latter 
mechanism provides a molecular explanation for the 
inability of AIs to impair primary tumor growth in hHGF 
KI SCID mice and suggests that stroma-derived HGF 
controls tumor metabolism.
Our data show that HGF regulates the metabolic 
function of CRC cells in multiple ways. A first effect is 
transcriptional activation of the SLC2A1 gene, resulting 
in increased expression of the GLUT1 protein. GLUT1 
is the prototype of facilitated glucose transporters and 
is frequently overexpressed in tumors [37]. In CRC, 
expression of GLUT1 is strongly associated with disease 
progression and represents a validated predictive marker 
of poor prognosis [38, 39]. In rectal cancer patients, 
elevated GLUT1 expression is associated with high 
post-operative stage, presence of lymph node metastases 
and distal recurrence [40]. Higher GLUT1 levels may 
guarantee continuous glucose uptake, fueling glycolysis 
under low nutrient conditions. This possibility may 
represent a significant survival advantage for CRC cells 
when continuous glucose supply is compromised by anti-
angiogenic therapy.
A second way by which HGF may influence CRC 
metabolism and contribute to maintain energy balance 
under starvation is through promotion of autophagy. 
Autophagy is an evolutionally conserved catabolic process 
by which cells destroy and recycle their macromolecules 
under metabolic stress in order to prevent an energetic 
crash [41]. HGF-mediated potentiation of autophagy 
may allow CRC cells to survive long enough until the 
‘famine’ period is over, thus increasing the chances of 
escaping drug-induced nutrient deprivation and promoting 
resistance.
As for all the other tissues, the growth and survival 
of tumors depends on blood supply, which brings 
oxygen and nutrients. For some reason, however, most 
attention has been concentrated in the last two decades 
on the possibility to ‘suffocate’ the tumor (by reducing 
its oxygenation) rather than to ‘starve’ it (by hijacking 
its access to glucose). But is oxygen deprivation the real 
biological mechanism underlying the anti-tumor effect of 
AIs? Or on the contrary, is it a trigger for the malignant 
adaptation of cancer cells, leading to acquired resistance 
and disease progression?
The cell-based experiments aimed at dissecting 
the biological effects of anti-angiogenic therapy on CRC 
cells provide support for the latter hypothesis. In fact, all 
CRC cells tested, regardless of their genetic status, were 
relatively resistant to hypoxia, which had a mere cytostatic 
effect, but more sensitive to both glucose deprivation 
and GLUT1 blockade, which caused apoptosis. This 
dichotomy was particularly evident in KRAS/BRAF-mutant 
cells: while hypoxia increased their invasiveness and 
aggressiveness, prolonged hypoglycemia was completely 
incompatible with their survival. Altogether, these data 
point at nutrient rather than oxygen dependency as the real 
Achille’s heel of KRAS- and BRAF-mutant tumors.
By pruning tumor blood vessels, AIs do deprive 
cancer cells of nutrients, thus in principle targeting this 
dependency, but at the same time cause tumor hypoxia, 
which represents a major stimulus for invasion and 
resistance. The data presented here suggest that, when 
inhibiting tumor angiogenesis, the benefits of reducing 
glucose availability are negatively compensated by the 
adverse effects of tumor hypoxia. In contrast, selective 
blockade of glucose metabolism achieves tumor 
starvation -which is what counts from a therapeutic 
viewpoint- without altering tumor oxygenation. Based on 
these results, it could be inferred that targeting glucose 
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Figure 11: Pharmacological GLUT1 blockade impairs colorectal cancer cell survival which can be rescued by paracrine 
HGF signaling. A. HCT-116 and HT-29 cells were cultured in the presence of increasing WZB-117 concentrations and in the absence or 
presence of HGF, and cell viability was determined by total ATP analysis. UCs, untreated cells. B. HCT-116 and HT-29 cells were incubated 
in decreasing concentrations of glucose, with 0 μmol/L or 20 μmol/L WZB-117 (WZB), and in the absence or presence of HGF. Apoptosis 
was determined by flow cytometry using the annexin/propidium iodide method. C. Luciferase-expressing tumor cells (TCs; HCT-116-luc 
or HT-29-luc) were seeded alone or together with human colon myofibroblasts (MFs) secreting approximately 1 μmol HGF/106 cells/24 
hours and then treated with 0 μmol/L or 20 μmol/L WZB-117 in the absence or presence of ficlatuzumab (FCL). Tumor cell viability was 
determined by measuring luciferase (LUC) activity. Values represent mean ± SEM. Statistical significance was calculated using a Student’s 
T-test (n = 3).
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Figure 12: Concomitant inhibition of HGF/MET signaling and glucose uptake suppresses colorectal tumor growth and 
metastasis in human HGF knock-in mice. A. HCT-116-luc and HT-29-luc cells were orthotopically injected into human HGF knock-
in (hHGF KI) SCID mice, and tumor-bearing mice were randomly assigned to 4 treatment arms: control (CTR); 20 mg/kg ficlatuzumab 
(FCL); 10 mg/kg WZB-117 (WZB); 10 mg/kg WZB-117 plus 20 mg/kg ficlatuzumab (WZB+FCL). Tumor growth was followed over time 
by in vivo bioluminescence (IVBL). B. Hepatic and pulmonary metastases in mice bearing HCT-116 or HT-29 tumors were determined 
by ex vivo bioluminescence (EVBL) analysis of explanted organs. C. Tumor hypoxia was determined by IHC analysis of HCT-116 and 
HT-29 tumor sections stained with anti-carbonic anhydrase IX (CAIX) antibodies. Unlike utter vessel blockade by bevacizumab (BEV) 
and tivozanib (TIV), glucose uptake impairment by WZB-117 does not exacerbate tumor hypoxia. The BEV and TIV images come from 
the experiment described in Figures 1-3. Bar size: 250 μm. Values represent mean ± SEM. Statistical significance was calculated using a 
Student’s T-test (n = 7).
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metabolism in CRC patients bearing KRAS- or BRAF-
mutant tumors may be a safer and more effective strategy 
compared to utterly impairing tumor angiogenesis.
A variety of metabolism-targeting drugs are about to 
reach the clinic, including inhibitors of glucose uptake and 
utilization [42]. The availability of highly specific, clinical 
grade drugs will allow running dedicated clinical trials on 
CRC patients bearing KRAS- and BRAF-mutant tumors 
that compare the efficacy and safety of metabolism-
targeting agents with that of angiogenesis inhibitors. Also, 
control of tumor metabolism by HGF may bring new 
life to the many HGF/MET inhibitors that are currently 
struggling to find an application in oncology. Possibly, 
the combined use of anti-metabolic agents and HGF/
MET-targeted drugs (‘anti-METabolic therapy’) may be 
considered in order to unmask metabolic addictions and, 




All tumor and stroma cell lines used in this 
study were purchased from the American Type Culture 
Collection (ATCC) and cultured as indicated by the 
provider. See online Suppl. Methods for more information 
on culturing conditions. Genetic identity of each cell line 
was confirmed by short tandem repeat profiling using Cell 
ID System (Promega).
Orthotopic model of colorectal carcinoma
All animal protocols were approved by the Animal 
Research Ethical Committee, Fondazione Piemontese per 
la Ricerca sul Cancro - ONLUS, Candiolo, Italy, and by 
the Italian Ministry of Health. WT SCID CB17 SCID mice 
were purchased from Charles River. The hHGF KI SCID 
strain was obtained from AVEO Pharmaceuticals and 
has been described previously [30]. Orthotopic injection 
of HCT-116-luc or HT-29-luc cells was performed as 
described [43]. See online Suppl. Methods for a detailed 
protocol description and for more information on drug 
administration, in vivo and ex vivo bioluminescence 
analysis, and immunohistochemical examination of 
tumors.
Oxygen versus glucose deprivation analysis
Cells were cultured in standard conditions until 
they reached 60% confluency, and then incubated in 
progressively lower concentrations of oxygen (21-0.1%) 
or glucose (4.5-0.01 g/L) in the absence or presence of 
50 ng/ml human recombinant HGF (R&D Systems). After 
48 hours, cells were processed for apoptosis and cell 
cycle analysis. For apoptosis analysis, cells were stained 
with a solution containing anti-annexin V antibodies 
and propidium iodide (eBioscience). The percentage of 
annexin V/propidium iodide-positive cells was determined 
by flow cytometry using a CyAnTM ADP analyzer 
(Beckman Coulter). Cell cycle analysis was determined as 
described [44]. For hypoxia-induced invasion and RT-PCR 
analysis please refer to online Suppl. Methods.
Metabolic analysis
Glucose and lactate concentration in the medium 
was determined using commercial kits (both from 
BioVision). For glucose uptake analysis, HCT-116 and 
HT-29 cells were pre-cultured in 4.5 g/L or 0.5 g/L glucose 
in the presence or absence of 50 ng/ml recombinant human 
HGF (R&D Systems) for 24 hours, and then incubated 
with 10 µmol/L 2-NBDG (Life Technologies) in glucose-
free medium for 30 minutes. The 2-NBDG reaction was 
stopped by washing cells with pre-chilled PBS. Glucose 
uptake was quantified by measuring the fluorescent 
intensity of cells in the FL-1 channel using a CyAnTM 
ADP analyzer (Beckman Coulter). For glycolytic capacity 
analysis, the extracellular acidification rate (ECAR) was 
determined using a Seahorse XF96 analyzer (Seahorse 
Bioscience) as described [45]. See online Suppl. Methods 
for more details.
Statistical analysis
Statistical significance was determined using a 
homoscedastic, two-tailed Student’s t-test. A p value ≤ 
0.05 was considered significant. In all Figures, values are 
expressed as mean of biological replicates ± SEM. Sample 
size is indicated in each Figure legend.
Abbreviations
CRC, colorectal cancer; HGF, Hepatocyte Growth 
Factor; AI, angiogenesis inhibitor; EGFR, Epidermal 
Growth Factor Receptor; VEGF, Vascular Endothelial 
Growth Factor; WT, wild-type; KI, knock-in; SCID, 
severe combined immuno-deficiency syndrome; luc, 
luciferase; CAIX, carbonic anhydrase IX; CTR, control; 
BEV, bevacizumab; TIV, tivozanib; JNJ, JNJ-38877605; 
FCL, ficlatuzumab; IVBL, in vivo bioluminescence; MVD, 
mean vessel density; MFI, mean fluorecent intensity.
Author contributions
A.M. designed, organized and performed most of the 
experimental work, analyzed data and interpreted results. 
Oncotarget38211www.impactjournals.com/oncotarget
V.M. offered skilled assistance for microsurgery. M.V.C. 
and R.M. provided the know-how for the orthotopic 
model. T.P. provided JNJ-38877605. P.M.C. provided 
intellectual input. P.M. conceived the project, supervised 
the work and wrote the manuscript.
ACKNOWLEDGMENTS
We thank Livio Trusolino, Andrea Bertotti, Claudio 
Isella and Enzo Medico for helpful discussion, William 
Rideout 3rd and May Han for hHGF KI SCID mice, Jeno 
Gyuris and Zhigang Weng for tivozanib and ficlatuzumab, 
and Stefania Giove for skilled technical assistance.
CONFLICTS OF INTEREST
The authors declare no conflict of interest for this 
manuscript.
FUNDING
This work has been supported in part by the 
Associazione Italiana per la Ricerca sul Cancro (AIRC; 
2010 Special Program in Molecular Clinical Oncology 
5‰ #9970 to P.M. and P.M.C., 2012 IG #12798 and 
2015 IG #17489 to P.M.), the Instituto de Salud Carlos 
III (co-funding from FEDER; grant PI12/01861 to R.M.), 
and CIBER-BBN (Intramural Grant Nanomets to R.M.). 
A.M. was supported by a Fondazione Umberto Veronesi 
Fellowship.
REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA 
Cancer J Clin. 2015; 65:5-29.
2. Fakih MG. Metastatic colorectal cancer: current state and 
future directions. J Clin Oncol. 2015; 33:1809-1824.
3. Dienstmann R, Salazar R, Tabernero J. Personalizing colon 
cancer adjuvant therapy: selecting optimal treatments for 
individual patients. J Clin Oncol. 2015; 33:1787-1796.
4. Van Cutsem E, Ducreux M. Colorectal and gastric cancer 
in 2015: The development of new agents and molecular 
classifications. Nat Rev Clin Oncol. 2016; 13:69-70.
5. Strickler JH, Hurwitz HI. Bevacizumab-based therapies 
in the first-line treatment of metastatic colorectal cancer. 
Oncologist. 2012; 17:513-524.
6. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone 
A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone 
C, Adenis A, Tabernero J, Yoshino T, et al. Regorafenib 
monotherapy for previously treated metastatic colorectal 
cancer (CORRECT): an international, multicentre, 
randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 
381:303-312.
7. Strickler JH, Hurwitz HI. Bevacizumab-based therapies 
in the first-line treatment of metastatic colorectal cancer. 
Oncologist. 2012; 17:513-524.
8. Van Cutsem E, Lambrechts D, Prenen H, Jain RK, 
Carmeliet P. Lessons from the adjuvant bevacizumab trial 
on colon cancer: what next? J Clin Oncol. 2011; 29:1-4.
9. Patel SR, Karnad AB, Ketchum NS, Pollock BH, 
Sarantopoulos J, Weitman S, Mahalingam D. Should we 
move beyond VEGF inhibition in metastatic colorectal 
cancer? Lessons from early phase clinical trials. J 
Gastrointest Oncol. 2014; 5:99-103.
10. Ulivi P, Marisi G, Passardi A. Relationship between 
hypoxia and response to antiangiogenic therapy in 
metastatic colorectal cancer. Oncotarget. 2016; 7:46678-
46691. doi: 10.18632/oncotarget.8712.
11. Rapisarda A, Melillo G. Role of the hypoxic tumor 
microenvironment in the resistance to anti-angiogenic 
therapies. Drug Resist Updat. 2009; 12:74-80.
12. Pennacchietti S, Michieli P, Galluzzo M, Mazzone 
M, Giordano S, Comoglio PM. Hypoxia promotes 
invasive growth by transcriptional activation of the met 
protooncogene. Cancer Cell. 2003; 3:347-361.
13. Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu 
YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, 
Marshall R, Perry A, Bjorgan KM, et al. Gene expression 
profile identifies tyrosine kinase c-Met as a targetable 
mediator of antiangiogenic therapy resistance. Clin Cancer 
Res. 2013; 19:1773-1783.
14. Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, 
Williamson CW, Bhagwandin V, Tabruyn SP, You WK, 
Chapman HA, Christensen JG, Aftab DT, McDonald DM. 
Suppression of tumor invasion and metastasis by concurrent 
inhibition of c-Met and VEGF signaling in pancreatic 
neuroendocrine tumors. Cancer Discov. 2012; 2:270-287.
15. Jiménez-Valerio G, Martínez-Lozano M, Bassani N, Vidal 
A, Ochoa-de-Olza M, Suárez C, García-Del-Muro X, 
Carles J, Viñals F, Graupera M, Indraccolo S, Casanovas 
O. Resistance to Antiangiogenic Therapies by Metabolic 
Symbiosis in Renal Cell Carcinoma PDX Models and 
Patients. Cell Rep. 2016; 15:1134-1143.
16. Allen E, Miéville P, Warren CM, Saghafinia S, Li L, Peng 
MW, Hanahan D. Metabolic Symbiosis Enables Adaptive 
Resistance to Anti-angiogenic Therapy that Is Dependent 
on mTOR Signaling. Cell Rep. 2016; 15:1144-1160.
17. Pisarsky L, Bill R, Fagiani E, Dimeloe S, Goosen RW, 
Hagmann J, Hess C, Christofori G. Targeting Metabolic 
Symbiosis to Overcome Resistance to Anti-angiogenic 
Therapy. Cell Rep. 2016; 15:1161-1174.
18. Trusolino L, Bertotti A, Comoglio PM. MET signalling: 
principles and functions in development, organ regeneration 
and cancer. Nat Rev Mol Cell Biol. 2010; 11:834-848.
19. Gherardi  E, Birchmeier W, Birchmeier C, Vande Woude G. 
Targeting MET in cancer: rationale and progress. Nat Rev 
Cancer. 2012; 12:89-103.
20. Vermeulen L, De Sousa E Melo F, van der Heijden M, 
Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro 
Oncotarget38212www.impactjournals.com/oncotarget
M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel 
DJ, et al. Wnt activity defines colon cancer stem cells and 
is regulated by the microenvironment. Nat Cell Biol. 2010; 
12:468-476.
21. Samamé Pérez-Vargas JC, Biondani P, Maggi C, Gariboldi 
M, Gloghini A, Inno A, Volpi CC, Gualeni AV, di 
Bartolomeo M, de Braud F, Castano A, Bossi I, Pietrantonio 
F. Role of cMET in the development and progression of 
colorectal cancer. Int J Mol Sci. 2013; 14:18056-18077.
22. Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner 
I, Birchmeier W, Schlag PM. MACC1, a newly identified 
key regulator of HGF-MET signaling, predicts colon cancer 
metastasis. Nat Med. 2009; 15: 59-67.
23. Perdomo G, Martinez-Brocca MA, Bhatt BA, Brown NF, 
O’Doherty RM, Garcia-Ocaña A. Hepatocyte growth factor 
is a novel stimulator of glucose uptake and metabolism in 
skeletal muscle cells. J Biol Chem. 2008; 283:13700-13706.
24. Bertola A, Bonnafous S, Cormont M, Anty R, Tanti JF, 
Tran A, Le Marchand-Brustel Y, Gual P. Hepatocyte 
growth factor induces glucose uptake in 3T3-L1 adipocytes 
through a Gab1/phosphatidylinositol 3-kinase/Glut4 
pathway. J Biol Chem. 2007; 282:10325-10332.
25. Brauer HA, Makowski L, Hoadley KA, Casbas-
Hernandez P, Lang LJ, Romàn-Pèrez E, D’Arcy M, 
Freemerman AJ, Perou CM, Troester MA. Impact of tumor 
microenvironment and epithelial phenotypes on metabolism 
in breast cancer. Clin Cancer Res. 2013; 19:571-585.
26. Cecchi F, Lih CJ, Lee YH, Walsh W, Rabe DC, Williams 
PM, Bottaro DP. Expression array analysis of the 
hepatocyte growth factor invasive program. Clin Exp 
Metastasis. 2015; 32:659-676.
27. Ikebuchi F, Oka K, Mizuno S, Fukuta K, Hayata D, Ohnishi 
H, Nakamura T. Dissociation of c-Met phosphotyrosine 
sites in human cells in response to mouse hepatocyte growth 
factor but not human hepatocyte growth factor: the possible 
roles of different amino acids in different species. Cell 
Biochem Funct. 2013; 31:298-304.
28. Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya 
N, Zhao P, Cao B, Tsarfaty G, Wang LM, Hay R, Vande 
Woude GF. Enhanced growth of human met-expressing 
xenografts in a new strain of immunocompromised mice 
transgenic for human hepatocyte growth factor/scatter 
factor. Oncogene. 2005; 24:101-106.
29. Luraghi P, Reato G, Cipriano E, Sassi F, Orzan F, Bigatto 
V, De Bacco F, Menietti E, Han M, Rideout WM 3rd, 
Perera T, Bertotti A, Trusolino L, et al. MET signaling in 
colon cancer stem-like cells blunts the therapeutic response 
to EGFR inhibitors. Cancer Res. 2014; 74:1857-1869.
30. Pennacchietti S, Cazzanti M, Bertotti A, Rideout WM 3rd, 
Han M, Gyuris J, Perera T, Comoglio PM, Trusolino L, 
Michieli P. Microenvironment-derived HGF overcomes 
genetically determined sensitivity to anti-MET drugs. 
Cancer Res. 2014; 74:6598-6609.
31. Cowey CL. Profile of tivozanib and its potential for the 
treatment of advanced renal cell carcinoma. Drug Des 
Devel Ther. 2013; 7:519-527.
32. Heijmen L, Ter Voert EG, Punt CJ, Heerschap A, Oyen WJ, 
Bussink J, Sweep CG, Laverman P, Span PN, de Geus-Oei 
LF, Boerman OC, van Laarhoven HW. Monitoring hypoxia 
and vasculature during bevacizumab treatment in a murine 
colorectal cancer model. Contrast Media Mol Imaging. 
2014; 3:237-245.
33. Nardo G, Favaro E, Curtarello M, Moserle L, Zulato E, 
Persano L, Rossi E, Esposito G, Crescenzi M, Casanovas O, 
Sattler U, Mueller-Klieser W, Biesalski B, et al. Glycolytic 
phenotype and AMP kinase modify the pathologic response 
of tumor xenografts to VEGF neutralization. Cancer Res. 
2011; 71:4214-4225.
34. Selvakumaran M, Amaravadi RK, Vasilevskaya IA, 
O’Dwyer PJ. Autophagy inhibition sensitizes colon cancer 
cells to antiangiogenic and cytotoxic therapy. Clin Cancer 
Res. 2013; 19:2995-3007.
35. Tabernero J, Elez ME, Herranz M, Rico I, Prudkin L, 
Andreu J, Mateos J, Carreras MJ, Han M, Gifford J, Credi 
M, Yin W, Agarwal S, et al. A pharmacodynamic/pharma-
cokinetic study of ficlatuzumab in patients with advanced 
solid tumors and liver metastases. Clin Cancer Res. 2014; 
20:2793-2804. 
36. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, 
Colvin R, Ding J, Tong L, Wu S, Hines J, Chen X. A small-
molecule inhibitor of glucose transporter 1 downregulates 
glycolysis, induces cell-cycle arrest, and inhibits cancer 
cell growth in vitro and in vivo. Mol Cancer Ther. 2012; 
11:1672-1682.
37. Scheepers A, Joost HG, Schürmann A. The glucose 
transporter families SGLT and GLUT: molecular basis of 
normal and aberrant function. JPEN J Parenter Enteral Nutr. 
2004; 28:364-371.
38. Shen YM, Arbman G, Olsson B, Sun XF. Overexpression 
of GLUT1 in colorectal cancer is independently associated 
with poor prognosis. Int J Biol Markers. 2011; 26:166-172.
39. Goos JA, de Cuba EM, Coupé VM, Diosdado B, Delis-Van 
Diemen PM, Karga C, Beliën JA, Menke-Van der Houven 
van Oordt CW, Geldof AA, Meijer GA, Hoekstra OS, 
Fijneman RJ, DeCoDe PET Group. Glucose Transporter 
1 (SLC2A1) and Vascular Endothelial Growth Factor A 
(VEGFA) Predict Survival after Resection of Colorectal 
Cancer Liver Metastasis. Ann Surg. 2016; 263:138-145.
40. Saigusa S, Toiyama Y, Tanaka K, Okugawa Y, Fujikawa 
H, Matsushita K, Uchida K, Inoue Y, Kusunoki M. 
Prognostic significance of glucose transporter-1 (GLUT1) 
gene expression in rectal cancer after preoperative chemo-
radiotherapy. Surg Today. 2012; 42:460-469.
41. Wang C, Hu Q, Shen HM. Pharmacological inhibitors of 
autophagy as novel cancer therapeutic agents. Pharmacol 
Res. 2016; 105:164-175.
42. Vander Heiden MG. Targeting cancer metabolism: a 
therapeutic window opens. Nat Rev Drug Discov. 2011; 
10:671-684.
Oncotarget38213www.impactjournals.com/oncotarget
43. Basilico C, Hultberg A, Blanchetot C, de Jonge N, Festjens 
E, Hanssens V, Osepa SI, De Boeck G, Mira A, Cazzanti M, 
Morello V, Dreier T, Saunders M, et al. Four individually 
druggable MET hotspots mediate HGF-driven tumor 
progression. J Clin Invest. 2014; 124:3172-3186.
44. Basilico C, Pennacchietti S, Vigna E, Chiriaco C, Arena S, 
Bardelli A, Valdembri D, Serini G, Michieli P. Tivantinib 
(ARQ197) displays cytotoxic activity that is independent 
of its ability to bind MET. Clin Cancer Res. 2013; 19:2381-
2392.
45. Dalva-Aydemir S, Bajpai R, Martinez M, Adekola KU, 
Kandela I, Wei C, Singhal S, Koblinski JE, Raje NS, Rosen 
ST, Shanmugam M. Targeting the metabolic plasticity 
of multiple myeloma with FDA-approved ritonavir and 
metformin. Clin Cancer Res. 2015; 5:1161-1171.
